10 registrations that name mitoquinone as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
9US sites across 7 states
1
2 to 4
5 to 19
20 or more
All 10 registrations
RecruitingNCT06191965
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Phase 2 and 3
Mclean Hospital
About 100 people
Started Jun 1, 2024
In plain words A Phase 2 and 3 study of mitoquinone in people 18 to 35, run by Mclean Hospital. It plans to enroll about 100 people at 3 sites, 2 of them in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 35. Conditions: Schizophrenia and Related Disorders; Mitochondrial Alteration; Cognitive Impairment.
Male or female aged 18 to 35 years old
Patients who have been diagnosed with one of the following schizophrenia-spectrum disorders: schizophreniform disorder, schizophrenia, schizoaffective disorder, unspecified psychosis.
Less than five years in treatment for psychosis (note that the duration of psychosis may be longer than 5 years, but this is more difficult to ascertain and therefore less reliable as an inclusion criterion).
PANSS score < 75
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
MitoQ; Placebo
Registered summary
The goal of this double-blind, placebo-controlled randomized clinical trial is to test the effect of 12 weeks of orally administered MitoQ (mitoquinol mesylate) supplementation on cognition in 50 people with early phase schizophrenia-spectrum disorders (E-SSD) who have mitochondrial dysfunction (called high risk, or HR). Cognitive impairments in SSD can cause significant disability. Yet, there are no effective treatments for cognitive impairments in SSD. It has been shown that alterations in a certain type of brain cell (parvalbumin interneurons, or PVI) underlie cognitive deficits in SSD. The full summary is on the listing.
Where, as registered
2 US sites in 2 states; also Switzerland (1).
RecruitingNCT05373043
Long-term COVID and Rehabilitation
No phase
VA Office of Research and Development
About 300 people
Started Nov 1, 2022
In plain words A study of mitoquinone in people 18 and older, run by VA Office of Research and Development. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Long-COVID.
Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis
Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis
Ability to sign informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Mitoquinone; Placebo
Registered summary
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function and minimize the long-term consequences of COVID-19.
Where, as registered
1 US site in 1 state.
RecruitingNCT07244809
Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity
No phase
University of Iowa
About 300 people
Started Oct 13, 2025
In plain words A study of mitoquinone in people 18 to 29, run by University of Iowa. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 29; healthy volunteers accepted. Conditions: Adverse Childhood Experience; Endothelial Function (FMD); Endothelial Injury; Mitochondrial Function; Oxidative Stress; Psychosocial Influence on Cardiovascular Disease.
18-29 years
ACE score >=4
The exclusion criteria are on the listing.
What it tests, as registered
Mitoquinone mesylate (MitoQ); Placebo
Registered summary
Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-level dysfunction. Greater exposure to ACEs are associated with greater increases in the risk of cardiovascular diseases and death. Our laboratory has previously observed that vascular function is disrupted in young adults with prior ACE exposure, even though these individuals appear to be healthy clinically (i.e., no classic clinical cardiovascular disease risk factors). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07229261
MitoQ to Improve Vascular Funciton in Preeclampsia
No phase
Medical College of Wisconsin
About 80 people
Started Mar 18, 2026
In plain words A study of mitoquinone in female participants 18 to 50, run by Medical College of Wisconsin. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 50. Conditions: Preeclampsia; Pregnancy.
Inpatient Cohort
pregnant patients with a clinical diagnosis of preeclampsia with severe features
gestational age between 23+0 and 33+0 weeks' gestation
singleton pregnancy
13 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Mitoquinol Mesylate; Placebo
Registered summary
Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. There is a lack of effective therapeutics for prevention or treatment. Our previous ex vivo work demonstrated that mitochondrial-antioxidants can reverse placental microvascular damage. Therefore, this study will evaluate whether MitoQ (Mitoquinol Mesylate, a mitochondrial-antioxidant) has the potential to restore vasodilation, improve placental function, and therefore promote pregnancy prolongation in patients with gestational hypertension (gHTN) and/or preeclampsia. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06027554
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Phase 2
UConn Health
About 60 people
Started Oct 7, 2024
In plain words A Phase 2 study of mitoquinone in people 65 to 80, run by UConn Health. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 80; healthy volunteers accepted. Conditions: Frailty; Mild Cognitive Impairment; Aging.
men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
The exclusion criteria are on the listing.
What it tests, as registered
Mitoquinone Mesylate; Placebo capsule
Registered summary
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive… The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06424756
Effects of an Antioxidant Supplement on Blood Vessel Health
Phase 2
University of Georgia
About 60 people
Started Jul 1, 2024
In plain words A Phase 2 study of mitoquinone in people 18 to 75, run by University of Georgia. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75; healthy volunteers accepted. Conditions: Healthy.
Self-identify as either non-Hispanic Black or non-Hispanic White.
Have low density lipoprotein cholesterol <150mg/dl.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
MitoQ; Placebo; MitoTempo; Tempol; L-NAME; SNP - Sodium Nitroprusside
Registered summary
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.
Where, as registered
1 US site in 1 state.
RecruitingNCT07142096
WinQ : a Window of Opportunity Study With MitoQ in Breast Cancer
No phase
Université Catholique de Louvain
About 20 people
Started Jul 20, 2025
In plain words A study of mitoquinone in female participants 18 and older, run by Université Catholique de Louvain. It plans to enroll about 20 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Breast Cancer.
Patients must meet the following criteria for study entry:
Signed Informed Consent Form (ICF)
Ability to comply with protocol, in the investigator's judgment
Women aged > 18 years (no limit of age)
26 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
MitoQ (mitoquinol mesylate)
Registered summary
The purpose of the study is to validate biomarkers in blood and tumor biopsy in patients with Triple Negative Breast Cancer, after a course of MitoQ treatment
Where, as registered
No US site; Belgium (2).
Not yet recruitingNCT07406243
Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women
No phase
Colorado State University
About 86 people
Starts Apr 2026 (estimated)
In plain words A study of mitoquinone in female participants 60 and older, run by Colorado State University. It plans to enroll about 86 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 60 and older. Conditions: Aging; Postmenopause.
Age 60 years or older;
Postmenopausal women defined as at least 1 year without menses as self-reported;
Estrogen-deficient; no hormone therapies (e.g., estrogen, progesterone, testosterone, DHEA, oral contraceptives, etc.) within the previous 6 months;
Ability to provide informed consent;
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Mitoquinone (MitoQ); Placebo
Registered summary
The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07228208
Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes
No phase
Medical College of Wisconsin
About 40 people
Starts Sep 1, 2026 (estimated)
In plain words A study of mitoquinone in people 18 to 80, run by Medical College of Wisconsin. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80; healthy volunteers accepted. Conditions: Type 2 Diabetes (T2DM); Endothelial Dysfunction.
Type 2 Diabetes: 18 - 80 years old, able to give informed consent, > 6 months post-diagnosis, > 6 months stable medications for management
Healthy controls: 18 - 80 years old, able to give informed consent
The exclusion criteria are on the listing.
What it tests, as registered
MitoQ (mitoquinol mesylate); Placebo
Registered summary
Exaggerated blood pressure responses to exercise in individuals with Type 2 Diabetes significantly increase the risk of heart attack, stroke, and cardiovascular death, while also limiting exercise capacity and therapeutic benefits of physical activity. This research will determine whether impaired blood vessel function and excessive cellular damage from oxygen-containing molecules cause these dangerous blood pressure responses during exercise. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07836777
Efficacy and Safety of MitoQ in Improving Cancer Cachexia
Phase 2
The First Affiliated Hospital of Xinxiang Medical College
About 20 people
Starts Oct 10, 2026 (estimated)
In plain words A Phase 2 study of mitoquinone in people 18 and older, run by The First Affiliated Hospital of Xinxiang Medical College. It plans to enroll about 20 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Cancer Cachexia (CC); Cancer Patients With Solid Tumors.
Subjects must meet all of the following inclusion criteria at screening to be eligible for enrollment in this study:
The exclusion criteria are on the listing.
What it tests, as registered
MitoQ (mitoquinol mesylate)
Registered summary
Muscle strength was evaluated in subjects with malignant solid tumors and cachexia after 12 weeks of oral MitoQ treatment.